Kamada Ltd. Q3 2025 Earnings Recap

KMDA Q3 2025 November 10, 2025

Get alerts when KMDA reports next quarter

Kamada Ltd. delivered robust performance in Q3 2025, achieving an 11% year-over-year revenue growth and a significant 35% increase in adjusted EBITDA, reinforcing its full-year guidance.

Earnings Per Share Miss

$0.09 vs $0.10 est.

-10.0% surprise

Revenue Miss

47010000 vs 147585500 est.

-68.1% surprise

Market Reaction

1-Day +0.57%

5-Day -2.56%

30-Day +0.0%

See KMDA alongside your other holdings

Add to your portfolio — free

Key Takeaways

Total revenues for the first nine months reached $135.8 million, with adjusted EBITDA at $34.2 million, highlighting strong operational efficiency.
The company is maintaining its 2025 revenue guidance of $178 million to $182 million and adjusted EBITDA of $40 million to $44 million.
Growth driven by increased demand for products like KedRAB and GALASIA, alongside strategic marketing initiatives for Cytogam and new biosimilars.
Active due diligence in potential M&A opportunities, expected to enhance product portfolio and accelerate commercial growth.
Progress on plasma collection centers in Houston and San Antonio, anticipated to generate $16 million to $20 million annually at full capacity.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit KMDA on AllInvestView.

Previous Q2 2025

Next Q1 2026